HDL cholesterol efflux capacity is related to disease activity in psoriatic arthritis patients.
Cholesterol efflux capacity
Disease activity
Dyslipidemia
Psoriatic arthritis
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
14
12
2019
accepted:
24
01
2020
revised:
22
01
2020
pubmed:
30
1
2020
medline:
17
2
2021
entrez:
30
1
2020
Statut:
ppublish
Résumé
Cholesterol efflux capacity (CEC) is the ability of high-density lipoprotein (HDL) cholesterol to accept cholesterol from macrophages. CEC is linked to cardiovascular events in the general population, and it has been shown to be disrupted in inflammatory states. The aim of this study was to establish whether CEC is impaired in PsA patients and if this could be explained by disease-related features like disease activity. Case-control study that encompassed 105 individuals: 52 PsA patients and 53 controls. CEC, using an in vitro assay, and lipoprotein serum concentrations were assessed in patients and controls. Disease activity in patients with PsA was measured using the Disease Activity Index for Psoriatic Arthritis (DAPSA). Multivariate analysis was performed to study the differences between CEC in patients and controls, and the relation of CEC with PsA activity-related data and lipid profile. Total cholesterol, apolipoprotein A1, and LDL cholesterol serum levels were downregulated in PsA patients. CEC did not differ between controls and patients (17 ± 10 vs. 18 ± 2%, p = 0.15) after adjusting for traditional cardiovascular risk factors or other variations in the lipid profile related to the disease. Traditional cardiovascular risk factors, both in patients and controls, were not related to CEC. After multivariate regression analysis, the DAPSA score was inversely and independently associated with CEC (beta coefficient - 0.75 [95%CI - 1.39-- 0.11] %, p = 0.023). CEC is inversely associated with disease activity in PSA patients, reinforcing the role of disease activity as a key factor in the development of accelerated atherosclerosis in these patients.Key Points• Cholesterol efflux capacity is linked to cardiovascular events in the general population.• In patients with psoriatic arthritis, cholesterol efflux capacity is inversely associated with disease activity (beta coefficient - 0.75[95% CI - 1.39-- 0.11] %, p = 0.023).• This finding reinforces the role of disease activity as a key factor in increasing cardiovascular risk in psoriatic arthritis patients.
Identifiants
pubmed: 31993889
doi: 10.1007/s10067-020-04961-4
pii: 10.1007/s10067-020-04961-4
doi:
Substances chimiques
Cholesterol, HDL
0
Lipids
0
Cholesterol
97C5T2UQ7J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1871-1880Subventions
Organisme : Instituto de Salud Carlos III
ID : PI15/01810
Organisme : Instituto de Salud Carlos III
ID : PI17/00083
Références
Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT (2009) Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 68:1131–1135
doi: 10.1136/ard.2008.094839
Jamnitski A, Symmons D, Peters MJ, Sattar N, McInnes I, Nurmohamed MT (2013) Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 72:211–216
doi: 10.1136/annrheumdis-2011-201194
Eder L, Wu Y, Chandran V, Cook R, Gladman DD (2016) Incidence and predictors for cardiovascular events in patients with psoriatic arthritis. Ann Rheum Dis 75:1680–1686
doi: 10.1136/annrheumdis-2015-207980
Haroon M, Rafiq Chaudhry AB, Fitzgerald O (2016) Higher prevalence of metabolic syndrome in patients with psoriatic arthritis: a comparison with a control group of noninflammatory rheumatologic conditions. J Rheumatol 43:463–464
doi: 10.3899/jrheum.150757
Tobin AM, Veale DJ, Fitzgerald O, Rogers S, Collins P, O’Shea D, Kirby B (2010) Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J Rheumatol 37:1386–1394
doi: 10.3899/jrheum.090822
Jones SM, Harris CP, Lloyd J, Stirling CA, Reckless JP, McHugh NJ (2000) Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. Ann Rheum Dis 59:904–909
doi: 10.1136/ard.59.11.904
Tam LS, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, Li TK, Yu T, Zhu YE, Wong KC, Kun EW, Li EK (2008) Cardiovascular risk profile of patients with psoriatic arthritis compared to controls--the role of inflammation. Rheumatology (Oxford) 47:718–723
doi: 10.1093/rheumatology/ken090
Lazarevic MB, Vitic J, Mladenovic V, Myones BL, Skosey JL, Swedler WI (1992) Dyslipoproteinemia in the course of active rheumatoid arthritis. Semin Arthritis Rheum 22:172–178
doi: 10.1016/0049-0172(92)90017-8
Skoczynska AH, Turczyn B, Barancewicz-Losek M, Martynowicz H (2003) High-density lipoprotein cholesterol in patients with psoriatic arthritis. J Eur Acad Dermatol Venereol 17:362–363
doi: 10.1046/j.1468-3083.2003.00792_11.x
Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34:585–592
doi: 10.1016/j.semarthrit.2004.07.010
Cuchel M, Rader DJ (2006) Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation 113:2548–2555
doi: 10.1161/CIRCULATIONAHA.104.475715
Tall AR (2008) Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med 263:256–273
doi: 10.1111/j.1365-2796.2007.01898.x
Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364:127–135
doi: 10.1056/NEJMoa1001689
Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA, Shaul PW (2014) HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 371:2383–2393
doi: 10.1056/NEJMoa1409065
Tejera-Segura B, Macia-Diaz M, Machado JD, de Vera-Gonzalez A, Garcia-Dopico JA, Olmos JM, Hernandez JL, Diaz-Gonzalez F, Gonzalez-Gay MA, Ferraz-Amaro I (2017) HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis. Arthritis Res Ther 19:113
doi: 10.1186/s13075-017-1311-3
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, Group CS (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673
doi: 10.1002/art.21972
Schoels MM, Aletaha D, Alasti F, Smolen JS (2016) Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 75:811–818
doi: 10.1136/annrheumdis-2015-207507
Prevoo ML, van’t Hoff MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48
doi: 10.1002/art.1780380107
Pincus T, Swearingen C, Wolfe F (1999) Toward a multidimensional health assessment questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum 42:2220–2230
doi: 10.1002/1529-0131(199910)42:10<2220::AID-ANR26>3.0.CO;2-5
Quevedo-Abeledo JC, Rua-Figueroa I, Sanchez-Perez H, Tejera-Segura B, de Vera-Gonzalez A, Gonzalez-Delgado A, Llorca J, Gonzalez-Gay MA, Ferraz-Amaro I (2019) Disease damage influences cardiovascular risk reclassification based on carotid ultrasound in patients with systemic lupus erythematosus. J Rheumatol 46:483–491
doi: 10.3899/jrheum.180881
Gonzalez-Gay MA, Gonzalez-Juanatey C (2014) Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox. Ann Rheum Dis 73:1281–1283
doi: 10.1136/annrheumdis-2013-204933
Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, Gabriel SE (2011) Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 70:482–487
doi: 10.1136/ard.2010.135871
Robertson J, Peters MJ, McInnes IB, Sattar N (2013) Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 9:513–523
doi: 10.1038/nrrheum.2013.91
Charles-Schoeman C, Lee YY, Grijalva V, Amjadi S, FitzGerald J, Ranganath VK, Taylor M, McMahon M, Paulus HE, Reddy ST (2012) Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis 71:1157–1162
doi: 10.1136/annrheumdis-2011-200493
Ronda N, Favari E, Borghi MO, Ingegnoli F, Gerosa M, Chighizola C, Zimetti F, Adorni MP, Bernini F, Meroni PL (2014) Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 73:609–615
doi: 10.1136/annrheumdis-2012-202914
Ferraz-Amaro I, Hernandez-Hernandez MV, Tejera-Segura B, Delgado-Frias E, Macia-Diaz M, Machado JD, Diaz-Gonzalez F (2019) Effect of IL-6 receptor blockade on proprotein convertase subtilisin/kexin type-9 and cholesterol efflux capacity in rheumatoid arthritis patients. Horm Metab Res 51:200–209
doi: 10.1055/a-0833-4627
Bellan M, Bor S, Gibbin A, Gualerzi A, Favretto S, Guaschino G, Bonometti R, Rossini A, Sola D, Pedrazzoli R, Carnevale Schianca GP, Pirisi M, Sainaghi PP (2018) Inflammatory markers predict insulin sensitivity in active rheumatoid arthritis but not in psoriatic arthritis. Reumatismo 70:232–240
doi: 10.4081/reumatismo.2018.1061
van Mens LJJ, van de Sande MGH, van Kuijk AWR, Baeten D, Coates LC (2018) Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort. Ann Rheum Dis 77:251–257
doi: 10.1136/annrheumdis-2017-211998
Salaffi F, Ciapetti A, Carotti M, Gasparini S, Gutierrez M (2014) Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world. Biomed Res Int 2014:528105
doi: 10.1155/2014/528105
Shen J, Wong KT, Cheng IT, Shang Q, Li EK, Wong P, Kun EW, Law MY, Yip R, Yim I, Ying S, Li M, Li TK, Wong CK, Zhu TY, Lee JJ, Chang M, Lee AP, Tam LS (2017) Increased prevalence of coronary plaque in patients with psoriatic arthritis without prior diagnosis of coronary artery disease. Ann Rheum Dis 76:1237–1244
doi: 10.1136/annrheumdis-2016-210390
Szentpetery A, Healy GM, Brady D, Haroon M, Gallagher P, Redmond CE, Fleming H, Duignan J, Dodd JD, FitzGerald O (2018) Higher coronary plaque burden in psoriatic arthritis is independent of metabolic syndrome and associated with underlying disease severity. Arthritis Rheum 70:396–407
doi: 10.1002/art.40389
Holzer M, Wolf P, Curcic S, Birner-Gruenberger R, Weger W, Inzinger M, El-Gamal D, Wadsack C, Heinemann A, Marsche G (2012) Psoriasis alters HDL composition and cholesterol efflux capacity. J Lipid Res 53:1618–1624
doi: 10.1194/jlr.M027367
Holzer M, Wolf P, Inzinger M, Trieb M, Curcic S, Pasterk L, Weger W, Heinemann A, Marsche G (2014) Anti-psoriatic therapy recovers high-density lipoprotein composition and function. J Invest Dermatol 134:635–642
doi: 10.1038/jid.2013.359
Salahuddin T, Natarajan B, Playford MP, Joshi AA, Teague H, Masmoudi Y, Selwaness M, Chen MY, Bluemke DA, Mehta NN (2015) Cholesterol efflux capacity in humans with psoriasis is inversely related to non-calcified burden of coronary atherosclerosis. Eur Heart J 36:2662–2665
doi: 10.1093/eurheartj/ehv339
Bhatt A, Rohatgi A (2016) HDL cholesterol efflux capacity: cardiovascular risk factor and potential therapeutic target. Curr Atheroscler Rep 18:2
doi: 10.1007/s11883-015-0554-1
Ormseth MJ, Yancey PG, Solus JF, Bridges SL Jr, Curtis JR, Linton MF, Fazio S, Davies SS, Roberts LJ 2nd, Vickers KC, Kon V, Michael Stein C, Investigators T (2016) Effect of drug therapy on net cholesterol efflux capacity of high-density lipoprotein-enriched serum in rheumatoid arthritis. Arthritis Rheum 68:2099–2105
doi: 10.1002/art.39675
Liao KP, Playford MP, Frits M, Coblyn JS, Iannaccone C, Weinblatt ME, Shadick NS, Mehta NN (2015) The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc 4
Ronda N, Greco D, Adorni MP, Zimetti F, Favari E, Hjeltnes G, Mikkelsen K, Borghi MO, Favalli EG, Gatti R, Hollan I, Meroni PL, Bernini F (2015) Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism. Arthritis Rheum 67:1155–1164
doi: 10.1002/art.39039
Faresjo T, Faresjo A (2010) To match or not to match in epidemiological studies--same outcome but less power. Int J Environ Res Public Health 7:325–332
doi: 10.3390/ijerph7010325